These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
90 related items for PubMed ID: 1987897
1. [Tumor markers--personal experience. Ha-ras P21 in neuroblastoma: a new marker associating to patient's prognosis]. Tanaka T. Gan To Kagaku Ryoho; 1991 Jan; 18(1):143-50. PubMed ID: 1987897 [Abstract] [Full Text] [Related]
2. Ha-ras p21 in neuroblastoma: a new marker in prediction of patient outcome. Tanaka T. Prog Clin Biol Res; 1994 Jan; 385():275-80. PubMed ID: 7972221 [No Abstract] [Full Text] [Related]
3. Prognostic prediction in neuroblastomas: clinical significance of combined analysis for Ha-ras p21 expression and N-myc gene amplification. Tanaka T, Seeger RC, Tanabe M, Hiyama E, Shimoda H, Ida N. Cancer Detect Prev; 1994 Jan; 18(4):283-9. PubMed ID: 7982238 [Abstract] [Full Text] [Related]
4. Expression of Ha-ras oncogene products in human neuroblastomas and the significant correlation with a patient's prognosis. Tanaka T, Slamon DJ, Shimoda H, Waki C, Kawaguchi Y, Tanaka Y, Ida N. Cancer Res; 1988 Feb 15; 48(4):1030-4. PubMed ID: 3276397 [Abstract] [Full Text] [Related]
5. Expressions of N-myc and ras oncogene products in neuroblastoma and their correlations with prognosis. Nakada K, Fujioka T, Kitagawa H, Takakuwa T, Yamate N. Jpn J Clin Oncol; 1993 Jun 15; 23(3):149-55. PubMed ID: 8350488 [Abstract] [Full Text] [Related]
6. A significant association of Ha-ras p21 in neuroblastoma cells with patient prognosis. A retrospective study of 103 cases. Tanaka T, Slamon DJ, Shimada H, Shimoda H, Fujisawa T, Ida N, Seeger RC. Cancer; 1991 Sep 15; 68(6):1296-302. PubMed ID: 1873783 [Abstract] [Full Text] [Related]
7. Ha-ras oncogene product in human oral squamous cell carcinoma. Oku N, Shimada K, Itoh H. Kobe J Med Sci; 1989 Dec 15; 35(5-6):277-86. PubMed ID: 2699627 [Abstract] [Full Text] [Related]
13. Expression of type I interferon receptor and its relation with other prognostic factors in human neuroblastoma. Mejía C, Navarro S, Colamonici OR, Pellín A, Castel V, Llombart-Bosch A. Oncol Rep; 1999 Nov 15; 6(1):149-53. PubMed ID: 9864419 [Abstract] [Full Text] [Related]
16. N-myc gene amplification in neuroblastoma determined by the polymerase chain reaction. Norris MD, Haber M, Gilbert J, Kavallaris M, Marshall GM, Stewart BW. Prog Clin Biol Res; 1994 Nov 15; 385():27-33. PubMed ID: 7972220 [No Abstract] [Full Text] [Related]
18. Induction of N-myc in neuroblastoma by autocrine IGF-II depends on farnesylated Ras. Application of farnesyltransferase inhibitors. Wittrock J, Schweizer P, Girgert R. Anticancer Res; 2002 Nov 15; 22(6C):4205-9. PubMed ID: 12553057 [Abstract] [Full Text] [Related]
19. Overexpression and amplification of c-myc and c-Ha-ras oncogenes in pleomorphic salivary adenoma. Xue H, Situ ZQ, Wang CJ, Wu JZ. Chin Med J (Engl); 1993 Jan 15; 106(1):22-5. PubMed ID: 8389270 [Abstract] [Full Text] [Related]
20. [c-myc and c-Ha-ras proto-oncogenes in cervical cancer: prognostic value]. Riou G, Sheng ZM, Zhou D, Lusinchi A, Le Doussal V, Barrois M. Bull Cancer; 1990 Jan 15; 77(4):341-7. PubMed ID: 2191730 [Abstract] [Full Text] [Related] Page: [Next] [New Search]